Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

• Главные авторы: Helena Iznardo (Автор), Esther Roé (Автор), Esther Serra-Baldrich (Автор), Lluís Puig (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2023-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response...